摘要
目的:评价在常规治疗基础上口服托伐普坦治疗充血性心力衰竭合并低钠血症的临床疗效。方法:选择2014年5月—2015年5月充血性心力衰竭合并低钠血症患者60例,随机分为试验组(30例,常规治疗+托伐普坦)和对照组(30例,常规治疗),分别在给药前后监测血钠,并记录患者用药前后的心功能指标、心力衰竭症状、体征、尿量、体重变化及不良反应。结果:试验组患者血清钠浓度明显高于对照组,试验组尿量增加、体重下降,心力衰竭症状、体征及心功能指标均优于对照组。结论:托伐普坦在不降低血钠浓度情况下可显著减轻容量负荷,改善大部分心力衰竭患者的临床症状及体征,不良反应发生率低,且可耐受。
Objective： To evaluate the clinical efficacy of tolvaptan on treating congestive heart failure patients with hyponatremia. Methods： Sixty patients who have congestive heart failure with hyponatremia from May 2014 to May 2015 in hospital were enrolled and randomly assigned to experimental group（ 30 cases,conventional treatment ＋ Tolvaptan） and control group（ 30 cases,conventional treatment）. After 7 days administration of the drug,all the patients were respectively followed everyday,were given at of the serum sodium,and the heart functions,signs and symptoms,volume,body weight and all adverse events were observed. Results： The sodium level was higher in tolvaptan group than in control group,volume increase,body weight decrease,signs and symptoms and heart functions were more significantly outperformed patients in control group. In this experiment,there were drug related adverse events of thirst and frequent urination in tolvaptan group,however,it could be well tolerated by patients. Conclusion： The effect of tolvaptan was proven by the increasing serum sodium concentration and reducing volume overload that could leads to marked improvement in signs and symptoms,and the related adverse events was low and could be well tolerated by patients. It has a certain clinical value on treating congestive heart failure patients with hyponatremia.
出处
《临床医药实践》
2016年第2期88-90,共3页
Proceeding of Clinical Medicine
